Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Atorvastatin (Lipitor)].

Y Carpentier1, J Ducobu, J Sternon

  • 1Centre d'Etudes et de Traitement des maladies cardio-vasculaires, Hôpital Erasme.

Revue Medicale De Bruxelles
|December 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemical identification and quantification of volatile organic compounds emitted by sewage sludge.

The Science of the total environment·2022
Same author

On the benefits of using multivariate analysis in mass spectrometric studies of combustion-generated aerosols.

Faraday discussions·2019
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

[Thyroid nodules: benign or malignant?].

Revue medicale de Bruxelles·2011
Same author

Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization.

Atherosclerosis·2011
Same author

Reversion of resistance to adriamycin by vanadate on 4 friend-cell sublines.

International journal of oncology·2011
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Atorvastatin, a synthetic statin, effectively lowers LDL cholesterol by inhibiting HMG-CoA reductase. It shows a good safety profile and is indicated for various hyperlipidemias.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Atorvastatin is a second-generation synthetic statin introduced in 1998.
  • It functions by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis.
  • This inhibition increases LDL receptors and reduces hepatic apo B production.

Purpose of the Study:

  • To review the mechanism of action, efficacy, indications, and safety of atorvastatin.
  • To assess its role in managing hypercholesterolemia.

Main Methods:

  • Review of atorvastatin's pharmacokinetic and pharmacodynamic properties.
  • Analysis of clinical data regarding its efficacy and safety profile.

Main Results:

  • Atorvastatin demonstrates high biological efficacy, lowering LDL by 41-61% depending on dosage.

Related Experiment Videos

  • Its prolonged half-life ensures sustained HMG-CoA reductase inhibition.
  • Common adverse effects are mild and gastrointestinal; liver and muscle enzyme alterations are rare.

    • Conclusions:

    • Atorvastatin is effective for primary hypercholesterolemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia.
    • It has a favorable safety profile with generally mild side effects.
    • Further clinical evidence on reducing cardiovascular morbidity and mortality could establish atorvastatin as a significant advancement in hypercholesterolemia treatment.